ストックスクリーナーアプリを入手
6.65
0.45%
-0.03
前日終値:
$6.68
開ける：
$6.75
24時間の取引高:
239.65K
Relative Volume:
0.62
時価総額：
$375.29M
収益：
-
当期純損益:
$-72.89M
株価収益率:
-2.7479
EPS:
-2.42
ネットキャッシュフロー:
$-68.47M
1週間 パフォーマンス:
-5.27%
1か月 パフォーマンス:
+4.40%
6か月 パフォーマンス:
-4.86%
1年 パフォーマンス:
-31.86%
1日の値動き範囲:
$6.535
$7.02
1週間の範囲:
$6.06
$7.18
52週間の値動き範囲:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
ATXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
6.65 | 376.98M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-29 | 開始されました | TD Cowen | Buy |
| 2023-03-28 | 開始されました | Evercore ISI | Outperform |
Astria Therapeutics Inc (ATXS) 最新ニュース
Signal strength of Astria Therapeutics Inc. stock in tech scannersMarket Risk Summary & Growth Focused Investment Plans - Newser
Shining A Light On Astria Therapeutics As Its Atopic Dermatitis Drug Approaches A Key Milestone - RTTNews
Astria Therapeutics Inc. stock momentum explainedMarket Activity Summary & Technical Pattern Based Buy Signals - Newser
Can Astria Therapeutics Inc. hit a new high this month [Earnings Overview Report]Free Risk Controlled Swing Trade Alerts - Newser
Astria Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
How high can Astria Therapeutics Inc. stock goRisk Aware Trading Ideas with Alert Levels - Newser
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - BioSpace
Price action breakdown for Astria Therapeutics Inc.Price Action & Risk Managed Investment Signals - Newser
Can Astria Therapeutics Inc. hit a new high this monthFree Smart Trade Plans With Risk Protection - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionAutomated AI Forecast with Trading Alerts - Newser
what makes astria therapeutics inc. stock price move sharplyFree Sector Rotation Based Trading Opportunities - Newser
Astria Therapeutics, Inc. SEC 10-Q Report - TradingView
Can trapped investors hope for a rebound in Astria Therapeutics Inc.Free Low Risk High Return Opportunities - Newser
Is it time to cut losses on Astria Therapeutics Inc.Pre-Market Stock Movement Summary and Review - Newser
What earnings revisions data tells us about Astria Therapeutics Inc.Weekly Chart Watchlist with Trade Guidance - Newser
How to build a dashboard for Astria Therapeutics Inc. stockWeekly Market Direction and Sector Summary - Newser
Will Astria Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsFree Market Momentum and Signal Alerts - Newser
How Astria Therapeutics Inc. stock performs during market volatilityFree Momentum Based Equity Trading Plan - Newser
Is Astria Therapeutics Inc. showing signs of accumulationInvestment Roadmap for High Potential Stocks - Newser
Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World
Astria Therapeutics Inc. stock prediction for this weekFree Smart Allocation Stock Pick Insights - Newser
Astria licenses rare disease drug Navenibart to Japan’s Kaken Pharma in $32 M deal - BioSpectrum Asia
Astria Therapeutics shares fall 1.15% intraday after being dropped from multiple Russell indices. - AInvest
Astria Therapeutics licenses navenibart rights to Kaken for HAE - Pharmaceutical Technology
How to escape a deep drawdown in Astria Therapeutics Inc.Chart Confirmation Setup with ROI Signals - Newser
Astria Therapeutics’ Strategic Advancements and Market Potential: A Buy Recommendation by Joseph Pantginis - TipRanks
Astria Therapeutics: Strategic Partnership and Promising Phase 3 Trial Justify Buy Rating - TipRanks
Astria Therapeutics Strikes Licensing Deal in Japan - MarketScreener
Astria Therapeutics Licenses Japan Rights to Navenibart in $16mln Deal, Kaken Pharmaceutical to Support Phase 3 Trials and Commercialization - AInvest
Astria Therapeutics Licenses Japan Rights To Navenibart In $16 Mln Deal - Nasdaq
Astria Therapeutics Enters Licensing Deal with Kaken - TipRanks
Astria, Kaken ink deal to develop navenibart for HAE in Japan - MarketScreener
ATXS inks $16M navenibart deal with Kaken; runway now into 2028 | ATXS SEC FilingForm 8-K - Stock Titan
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan - Business Wire
Astria Therapeutics Grants Stock Options to Two New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Astria Therapeutics Inc (ATXS) 財務データ
収益
当期純利益
現金流量
EPS
0.91%
3.06%
大文字化:
|
ボリューム (24 時間):